包膜下睾丸切除术与根治性睾丸切除术治疗转移性前列腺癌的比较。
Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate cancer.
作者信息
Zhang X Z, Donovan M P, Williams B T, Mohler J L
机构信息
Department of Surgery, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, 27599-7235, USA.
出版信息
Urology. 1996 Mar;47(3):402-4. doi: 10.1016/S0090-4295(99)80460-9.
OBJECTIVES
To determine whether subcapsular orchiectomy provides suboptimal treatment of metastatic prostate cancer when used to avoid the psychologic consequences of the empty scrotum that results from total orchiectomy.
METHODS
We compared testosterone and prostate-specific antigen levels and survival of 37 patients who underwent total orchiectomy and 37 patients who underwent subcapsular orchiectomy for metastatic prostate cancer.
RESULTS
The two groups of 37 patients were similar by clinical parameters. Postoperatively, testosterone levels were 21 +/- 11 ng/dL for subcapsular versus 21 +/- 9 ng/dL for total orchiectomy patients. Tumor response was similar in the two groups when assessed by prostate-specific antigen measured 3 weeks, 6 months, and 1, 2, and 3 years postoperatively. Survival was similar when assessed using Kaplan-Meier analysis (P = 0.76).
CONCLUSIONS
Subcapsular orchiectomy is a viable option for treatment of metastatic prostate cancer.
目的
确定当采用包膜下睾丸切除术以避免因根治性睾丸切除术导致的阴囊空虚所带来的心理影响时，其对转移性前列腺癌的治疗效果是否欠佳。
方法
我们比较了37例行根治性睾丸切除术的患者和37例行包膜下睾丸切除术的转移性前列腺癌患者的睾酮水平、前列腺特异性抗原水平及生存率。
结果
两组各37例患者的临床参数相似。术后，包膜下睾丸切除术患者的睾酮水平为21±11 ng/dL，根治性睾丸切除术患者为21±9 ng/dL。术后3周、6个月以及1、2和3年时通过前列腺特异性抗原评估，两组的肿瘤反应相似。采用Kaplan-Meier分析评估时，生存率相似（P = 0.76）。
结论
包膜下睾丸切除术是治疗转移性前列腺癌的一种可行选择。
Zotero 插件